Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II datopotamab deruxtecan in triple-negative breast cancer with active brain metastases
2022-003203-14Phase 2Active
- Sponsor
- Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darunavir + cobicistat in triple-negative breast cancer (TNBC), sponsored by Medical University of Vienna, Department of Internal Medicine I, Division of Oncology. Primary endpoint: Intracranial response rate. Started Dec 2022; status: active.
02
Drugs
darunavir + cobicistat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-003203-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003203-14.